CurrentmhnPolicy CP.CPA.313

Pyridostigmine (Mestinon) syrup prior authorization and coverage

Defines medical necessity criteria, prior authorization requirements, dosing limits, and formulary substitution rules for pyridostigmine (Mestinon) oral syrup for members under the commercial line of business.

Policy Summary

Payermhn

PolicyPyridostigmine (Mestinon) syrup prior authorization and coverage

Policy CodePolicy CP.CPA.313

Change TypeFormulary redirectionapproval duration revised

Effective DateAug 1, 2016

Next Review DateNov 25, 2025

Key ActionObtain prior authorization and submit documentation showing member meets all approval criteria; use generic pyridostigmine syrup before brand Mestinon unless contraindicated.

SourceLink

POLICY UPDATE CHANGES

Policy/criteria revised to also include generic pyridostigmine syrup and redirect brand requests to generic when appropriate per formulary status.

Approval duration for Commercial line of business revised to 12 months or duration of request, whichever is less.

1,500 mg/dayMaximum allowed daily dose

60 mg/5 mLSyrup concentration available

12 monthsApproval duration (commercial)

CommercialLine of business

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Initial Therapy — Myasthenia Gravis

Covered when ALL of the following are met:

Myasthenia Gravis initial approval: 1. Diagnosis of myasthenia gravis; 2. Documentation supports inability to use generic pyridostigmine tablets (e.g., inability to swallow pill due to young age, disease with bulbar involvement); 3. If request is for brand Mestinon syrup, member must use generic pyridostigmine syrup, unless contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed 1,500 mg per day.

Initial approval requires all conditions

Continuation Therapy — Myasthenia Gravis

Covered when ALL of the following are met:

Myasthenia Gravis continuation approval: 1. Member meets one of the following (a or b): (a) currently receiving medication via Centene benefit or member has previously met initial approval criteria; or (b) member is currently receiving medication and is enrolled in a state and product with continuity of care regulations; 2. Member is responding positively to therapy; 3. If request is for brand Mestinon syrup, member must use generic pyridostigmine syrup, unless contraindicated or clinically significant adverse effects are experienced; 4. If request is for a dose increase, new dose does not exceed 1,500 mg per day.

Approval duration: 12 months or duration of request, whichever is less

Other Diagnoses/Indications

Covered when ONE of the following is met:

Recent label change pathway: If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to the applicable formulary/no-coverage or non-formulary policies (e.g., CP.CPA.190) for coverage determination.

Follow referenced policies for coverage decisions

Off-label consideration pathway: If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 (recent label change) does not apply, refer to the off-label use policy CP.CPA.09 for evaluation for the commercial line of business.

Off-label uses considered per CP.CPA.09

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the request includes sufficient documentation demonstrating efficacy and safety in accordance with the off‑label use policy CP.CPA.09 for commercial members or applicable evidence of coverage documents.

Uses that are non‑FDA approved and lack sufficient supporting documentation per policy CP.CPA.09 are considered not medically necessary and are not covered.

Coding & Dosage

Product availability / NDCNDC

NDC	Not specified in document; product availability listed as oral syrup 60 mg/5 mL (473 mL bottle)

inv-07: Maximum daily dose

Maximum daily dose1,500 mg/day

Typical dosing range for myasthenia gravis60–1,500 mg/day divided into 5–6 doses

Dosing frequency guidanceDivide total daily dose into 5 to 6 doses spaced to provide maximum relief

Policy limit applicationDose must not exceed 1,500 mg per day for initial and continuation approvals

Provider Actions & Requirements

Prior Authorization

Prior authorization required

Prior authorization is required for pyridostigmine (Mestinon) oral syrup; provider must demonstrate the member meets all approval criteria for coverage.

Step Therapy

Formulary redirection to generic

Brand Mestinon syrup requests must use generic pyridostigmine syrup first unless the generic is contraindicated or the member has clinically significant adverse effects documented.

Documentation Required

Required documentation

Submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, or other information that demonstrates the member has met all approval criteria.

Background

Pyridostigmine (Mestinon) is a cholinesterase inhibitor indicated for the treatment of myasthenia gravis. The syrup formulation is used when tablets cannot be used (for example, inability to swallow, young age, or bulbar involvement). Typical dosing for myasthenia gravis ranges from 60–1,500 mg/day divided into multiple doses; the syrup concentration available is 60 mg/5 mL.

Definitions

inv-13: Mestinon (pyridostigmine)

DefinitionPyridostigmine (Mestinon) is a cholinesterase inhibitor indicated for treatment of myasthenia gravis.

Available formulationsOral syrup (60 mg/5 mL) and tablets

Typical dosingFor myasthenia gravis: 60–1,500 mg/day PO divided into 5–6 doses (average ~600 mg/day)

Syrup concentration and presentationSyrup concentration: 60 mg per 5 mL (available as 473 mL bottle)

Prior authorizationPrior authorization is required for the oral syrup formulation